: Table S1. Clinical characteristics of 89 NSCLCs in this study. Table S2. The post-alignment QC metrics information of WES. The post-alignment QC metrics information of WES including expected depth,
We conducted a phase II multicenter single arm trial of pembrolizumab and cabozantininb in patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma). We extracted DNA from 16 tumors an
Table S5. Empirical analysis of TMB association or predictive value for immunotherapy response. These analyses were performed on panel-based TMB values, directly calculated by panel sequencing. The ta
